Bank of America Corp DE boosted its stake in shares of ESSA Pharma Inc. (NASDAQ:EPIX - Free Report) TSE: EPI by 10,153,775.0% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 812,310 shares of the company's stock after acquiring an additional 812,302 shares during the quarter. Bank of America Corp DE owned 1.83% of ESSA Pharma worth $1,454,000 at the end of the most recent reporting period.
Several other institutional investors also recently bought and sold shares of the stock. Two Sigma Securities LLC purchased a new position in ESSA Pharma during the fourth quarter valued at approximately $29,000. Lepercq Multi Asset Fund purchased a new position in ESSA Pharma during the fourth quarter valued at approximately $54,000. XTX Topco Ltd purchased a new position in ESSA Pharma during the fourth quarter valued at approximately $67,000. Jane Street Group LLC purchased a new position in ESSA Pharma during the fourth quarter valued at approximately $82,000. Finally, Vazirani Asset Management LLC acquired a new stake in ESSA Pharma in the fourth quarter valued at approximately $90,000. 75.12% of the stock is currently owned by hedge funds and other institutional investors.
ESSA Pharma Price Performance
EPIX remained flat at $1.71 during trading on Friday. The company's stock had a trading volume of 76,303 shares, compared to its average volume of 341,167. ESSA Pharma Inc. has a one year low of $1.40 and a one year high of $7.88. The business's fifty day moving average price is $1.68 and its two-hundred day moving average price is $1.69. The company has a market cap of $75.91 million, a price-to-earnings ratio of -2.48 and a beta of 1.58.
ESSA Pharma (NASDAQ:EPIX - Get Free Report) TSE: EPI last issued its quarterly earnings data on Thursday, May 8th. The company reported ($0.14) EPS for the quarter, beating the consensus estimate of ($0.19) by $0.05. Equities research analysts forecast that ESSA Pharma Inc. will post -0.42 earnings per share for the current year.
About ESSA Pharma
(
Free Report)
ESSA Pharma Inc, a clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer. The company's lead candidate EPI-7386, an androgen receptor based resistance mechanisms that develop in patients with castration-resistant prostate cancer and metastatic castration-resistant prostate cancer.
Featured Stories
Before you consider ESSA Pharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ESSA Pharma wasn't on the list.
While ESSA Pharma currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
